NIH R01 · 2025
Improving immune modulation for smoldering myeloma
Summary All cases of multiple myeloma (MM) are preceded by precursor state termed as monoclonal gammopathy of undetermined significance (MGUS). Therefore targeting precursor states may be an effective approach to prevent this malignancy. In a recent randomized trial, we have shown that lenalidomide led to reduced risk of progression of smoldering myeloma (SMM) to clinical myeloma. In prior studies, we have shown that the immune system is capable of recognizing myeloma precursor lesions. In recent studies, we have also shown that immune dysfunction is an early feature of myeloma suggesting that earlier application of immune modulation may be needed to mediate immune prevention. In…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.